Stay updated with breaking news from Fred Schwarzer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) CEO Fred Schwarzer sold 17,576 shares of IGM Biosciences stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $5.78, for a total value of $101,589.28. Following the completion of the transaction, the chief executive officer now owns […]
By Denny Jacob IGM Biosciences will reduce its workforce by 22%, part of a broader overhaul within the company. The clinical-stage biotechnology company said...
– Third IND cleared for imvotamab in autoimmune diseases –
13.11.2023 - – Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) - IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage ...
- Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway - - Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444